Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 8, 2018

Primary Completion Date

December 6, 2023

Study Completion Date

December 6, 2023

Conditions

DCIS

Interventions

DRUG

Palbociclib

Palbociclib capsules for oral administration contain 125 mg, 100 mg, or 75 mg of palbociclib, a kinase inhibitor.

Trial Locations (2)

MedStar Georgetown University Hospital, Washington D.C.

Medstar Washington Hospital Center, Washington D.C.